赛诺菲免疫学全球研发负责人Alyssa Johnsen博士对此表示：“这一认定是对riliprubart解决关键医疗空白潜力的重要认可。 我们将全力加速其临床开发进程，目标是尽早为饱受AMR折磨的移植患者带来变革性的治疗方案。” ...

法国制药巨头赛诺菲公司宣布，美国FDA已授予其实验性药物riliprubart孤儿药资格认定，用于治疗实体器官移植中的抗体诱导排斥反应（RIA）。这一认定体现了赛诺菲致力于解决移植医学领域关键未满足需求的承诺，目前该领域仍面临重大挑战且尚无FDA批准 ...

Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...

In Japan alone, around 4,000 individuals have a CIDP diagnosis. Sanofi neurology development global head Erik Wallstroem ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to Riliprubart ...

Ongoing phase 2 study evaluating riliprubart for the potential prevention and treatment of active antibody-mediated rejection in kidney transplant recipients Riliprubart was also designated orphan ...

Japanese Ministry of Health, Labour and Welfare decision adds to similar designations in the US and Europe, underscoring global regulatory recognition of the potential for riliprupart to address ...

Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) announced that the FDA granted orphan drug designation to Riliprubart for ...

Paris: Sanofi has received orphan drug designation from the Ministry of Health, Labour and Welfare (MHLW) in Japan for ...